沙利文授予药明康德“2022全球CRDMO年度公司奖”
沙利文授予药明康德“2022全球CRDMO年度公司奖”
近日，弗若斯特沙利文（Frost & Sullivan，以下简称“沙利文”） 公布了2022年度“最佳实践奖”（Frost & Sullivan Best Practices Awards）评选结果。 基于对全球医药研发市场的调研和分析，以及对业内相关公司的研究和评估，沙利文决定授予药明康德“2022全球CRDMO年度公司奖”。这也是药明康德连续第六年获得该奖项。
沙利文“最佳实践奖”旨在表彰全球各领域在处于创新和增长前沿，不断为客户提供创新解决方案和杰出服务的公司。 沙利文认为，药明康德致力于满足医药健康行业不断变化的需求，凭借其强大的领导力，创造了卓越的客户价值，成为最佳实践公司的典范。 药明康德拥有一体化、全方位的赋能平台，通过独特的CRDMO和CTDMO业务模式，成为全球客户值得信赖的合作伙伴，不断助力客户推动创新药物的研发进程，造福全球病患。
沙利文医疗保健和生命科学总监Unmesh Lal表示，“药明康德独特的商业模式覆盖了整个新药研发价值链。此外，药明康德在靶向蛋白降解、寡核苷酸、多肽、抗体偶联药物、细胞和基因疗法（CGT）等新分子和创新疗法领域不断建能力、扩规模，以更好地赋能客户加速推进新药研发进程。”
“药明康德很荣幸获得2022全球CRDMO年度公司奖，感谢弗若斯特沙利文认可公司赋能平台为客户和医药健康行业创造的价值。”药明康德董事长兼首席执行官李革博士表示，“我们将继续不断加强能力和规模建设，助力全球合作伙伴加速新药研发进程，推动更多突破性治疗方案的早日问世，惠及全球患者。”
关于药明康德
公众号名称
药明康德（股票代码： 603259.SH/2359.HK）为全球生物医药行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。 药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。
2022年，药明康德被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的5900多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。
Frost & Sullivan Awarded WuXi AppTec 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award
Recently, Frost & Sullivan announced the results of the 2022 "Frost & Sullivan Best Practices Awards". Based on the research and analysis of the global pharmaceutical R&D market, as well as the research and evaluation of related companies in the industry, Frost & Sullivan decided to award WuXi AppTec the "2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award". This is also the sixth consecutive year that WuXi AppTec has won the award.
The Frost & Sullivan Best Practices Awards recognize companies at the forefront of innovation and growth, with an eye toward creating new products, solutions, and services as customer needs evolve. This award recognizes WuXi AppTec’s efforts to address customer demand and provide superior service value with a strong leadership focus. WuXi AppTec’s one-of-a-kind, fully integrated service models – CRDMO (Contract Research, Development and Manufacturing Organization) and CTDMO (Contract Testing, Development and Manufacturing Organization) – allow it to function as a trusted one-stop service enabler for customers to advance their innovative medicines to benefit patients worldwide.
Unmesh Lal, Director of Healthcare & Life Science at Frost & Sullivan commented, "WuXi AppTec's unique business model is well positioned to support the entire value chain for any synthetic molecules. Additionally, continuous investment into new modalities such as targeted protein degradation, oligonucleotide, peptide, antibody-drug conjugate, and CGT enables customers to improve and advance healthcare product development."
"We are honored to receive the 2022 Global Company of the Year Award from Frost & Sullivan, and we thank them for recognizing the value our CRDMO and CTDMO models bring to our customers and the industry," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "WuXi AppTec will continue to strengthen its capabilities and capacity to better support our customers’ efforts to bring groundbreaking therapies to patients around the world."
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.
WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 5,900 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
推荐阅读
👉 沙利文授予金山医疗机器人有限公司「中国医疗机器人创新奖」
👉 沙利文授予至本医疗「中国数字化肿瘤精准诊疗服务领先平台奖」
👉 沙利文授予上海百利佳生医药 科技 有限公司“ 2021 年中国生物医药CRO领域卓越创新奖”
👉 沙利文授予世和基因“2019沙利文中国 新 经济--卓越领导力奖”
👉 沙利文授予北海康成制药有限公司“2019沙利文中国新经济奖”
